MONARCH 3: Final overall survival results of abemaciclib plus a nonsteroidal aromatase inhibitor as first-line therapy for HR+, HER2-advanced breast cancer

被引：1
|
作者：
Goetz, Matthew
Toi, Masakazu
Huober, Jens
Sohn, Joo Hyuk
Tredan, Olivier
Park, Inhae
Campone, Mario
Chen, Shin-Cheh
Manso, Luis Manual
Paluch-Shimon, Shani
Freedman, Orit C.
Andre, Valerie
Saha, Abhijoy
van Hal, Gertjan
Shahir, Ashwin
Iwata, Hiroji
Johnston, Stephen R. D.
O'Shaughnessy, Joyce
Pivot, Xavier
Tolaney, Sara
Hurvitz, Sara
Llombart, Antonio
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-GS01-12
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
GS01-12
引用
收藏
页数：3
相关论文
共 50 条
  • [21] MONARCH 2: Abemaciclib in combination with fulvestrant in patients with HR+/HER2-advanced breast cancer who progressed on endocrine therapy
    Sledge, George W.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Inoue, Kenichi
    Pivot, Xavier B.
    Burdaeva, Olga Nikolaevna
    Okera, Meena
    Masuda, Norikazu
    Kaufman, Peter A.
    Koh, Han A.
    Grischke, Eva-Maria
    Frenzel, Martin
    Lin, Yong
    Barriga, Susana
    Smith, Ian C.
    Bourayou, Nawel
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Abemaciclib plus fulvestrant or nonsteroidal aromatase inhibitor in participants with HR+, HER2-breast cancer - A pooled analysis of the endocrine therapy-naive participants with measurable disease in MONARCH 2 and MONARCH 3
    Goetz, Matthew P.
    Trujillo, Jose Luis Gonzalez
    Toi, Masakazu
    Huober, Jens
    Llombart-Cussac, Antonio
    Zhang, Wei
    Knoderer, Holly
    Haddad, Nadine
    Van Hal, Gertjan
    Sledge, George W., Jr.
    CANCER RESEARCH, 2022, 82 (04)
  • [23] Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naive (EN) participants in MONARCH 2
    Luis-Gonzalez Trujillo, J.
    Escobar Gomez, M.
    Sohn, J. H.
    Im, Y-H.
    Wang, H-C.
    Cussac, A. Llombart
    Zhang, W.
    Haddad, N.
    Wasserstrom, H.
    van Hal, G.
    Sledge, G. W., Jr.
    ANNALS OF ONCOLOGY, 2021, 32 : S464 - S465
  • [24] HR+/HER2-Advanced Breast Cancer Treatment in the First-Line Setting: Expert Review
    Jerzak, Katarzyna J.
    Bouganim, Nathaniel
    Brezden-Masley, Christine
    Edwards, Scott
    Gelmon, Karen
    Henning, Jan-Willem
    Hilton, John F.
    Sehdev, Sandeep
    CURRENT ONCOLOGY, 2023, 30 (06) : 5425 - 5447
  • [25] Is There Still a Role for First-Line Single Agent Endocrine Therapy in HR+ and HER2-Advanced Breast Cancer?
    Malorni, Luca
    Biganzoli, Laura
    BREAST CARE, 2017, 12 (05) : 288 - 289
  • [26] Abemaciclib for pre/perimenopausal women with HR+, HER2-advanced breast cancer
    Neven, Patrick
    Rugo, Hope S.
    Tolaney, Sara M.
    Iwata, Hiroji
    Toi, Masakazu
    Goetz, Matthew P.
    Kaufman, Peter A.
    Barriga, Susana
    Lin, Yong
    Sledge, George W.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant
    Neven, P.
    Fasching, P. A.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S. -a.
    Petrakova, K.
    Bianchi, G. V.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    de la Cruz-merino, L.
    Beck, J. T.
    Zarate, J. P.
    Wang, Y.
    Chakravartty, A.
    Wang, C.
    Slamon, D. J.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [28] Updated subgroup tumor response of abemaciclib plus aromatase inhibitor for hormone receptor positive (HR+), HER2 negative advanced breast cancer (MONARCH 3)
    O'Shaughnessy, Joyce
    Johnston, Stephen
    Martin, Miguel
    Huober, Jens
    Toi, Masakazu
    Andre, Valerie AnneMarie
    Martin, Holly Rene
    Hardebeck, Molly Catherine
    Di Leo, Angelo
    Goetz, Matthew Philip
    CANCER RESEARCH, 2020, 80 (04)
  • [29] nextMONARCH 1: Phase 2 study of abemaciclib plus tamoxifen or abemaciclib alone in HR+, HER2-advanced breast cancer
    Hamilton, E.
    Cortes, J.
    Dieras, V.
    Ozyilkan, O.
    Chen, S-C
    Petrakova, K.
    Manikhas, A.
    Jerusalem, G.
    Hegg, R.
    Lu, Y.
    Bear, M. M.
    Johnston, E. L.
    Martin, M.
    CANCER RESEARCH, 2019, 79 (04)
  • [30] Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2-advanced breast cancer
    Corona, Silvia Paola
    Generali, Daniele
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 321 - 330
12345